ACT Capital Partners, L.P.’s Palvella Therapeutics PVLA Stock Holding History

ACT Capital Partners, L.P.’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.1M	Buy	+22,500	New	+$3.34M	2.02%	15

Other funds holding PVLA

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Clio Asset Management Charlottesville, Virginia $119M AUM 1.1% 1-Year Est. Return

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Lisanti Capital Growth New York $373M AUM 178.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return

ACT Capital Partners, L.P.'s PVLA Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in Palvella Therapeutics (PVLA) in Q3 2026: 22,500 shares worth $3.1M. The stake represents 2.02% of the portfolio and ranks #15 among its holdings.

67 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

ACT Capital Partners, L.P. held 22,500 shares of Palvella Therapeutics worth $3.1M as of Q3 2026.
Palvella Therapeutics was a new ACT Capital Partners, L.P. position in Q3 2026.
Palvella Therapeutics made up 2.02% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #15 holding.
67 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.